New treatment for CLL using alternating two drug types
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies an approach for people with newly diagnosed CLL/SLL (chronic lymphocytic leukemia or related disease) who need treatment. It tests whether alternating two types of chemotherapy with ibrutinib (a targeted pill) can control the disease better and safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to 75 years old and have a confirmed diagnosis of CLL or SLL.
- You have not had standard CLL treatment before (or only very limited short-term treatment, with specific limits).
- Your CLL is causing problems that mean you need treatment now (such as worsening anemia or low platelets, enlarged spleen/lymph nodes, rising lymphocyte counts, or weight loss/fatigue from the disease).
- Your day-to-day function is fairly good (ECOG 0 to 2) and you’re expected to live at least 3 more months.
- Your liver and kidneys are healthy enough for study drugs, and you do not have severe or uncontrolled infections or major bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether taking ibrutinib in a less continuous (“intermittent”) schedule can keep your chronic lymphocytic leukemia (CLL) under control. It’s for people who have already received ibrutinib for at least 6 months and had a good early response, aiming to reduce treatment intensity while tracking safety and cancer control.
This Phase 2 study tests a fixed-length treatment plan using ibrutinib plus obinutuzumab for people with newly diagnosed, active CLL/SLL that needs treatment. It may help control the leukemia/lymphoma by combining a targeted drug with an antibody therapy.
This trial tests two different combinations of targeted drugs for people with CLL or SLL who have not had prior treatment for their disease. The goal is to see if these combinations are safe and effective.
This trial tests a new investigational drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already tried two types of treatments (BTK and BCL2 inhibitors). The goal is to see if this new drug works better than other available treatments chosen by the doctor.
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and obinutuzumab) given for a limited time to people whose CLL/SLL has come back after prior treatment. The goal is to see if this combination can control the cancer and possibly allow a treatment-free period.
This trial tests a combination of two drugs, pirtobrutinib (a pill) and obinutuzumab (an infusion), given for a set period of time in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had any previous treatment for their disease. The goal is to see if this combination can control the cancer effectively.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.